Selected article for: "current study and increased number"
Author: Chuang, Chi-Mu; Monie, Archana; Hung, Chien-Fu; Wu, T-C
Title: Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
  • Cord-id: xndxn1r3
  • Document date: 2010_4_28
    • ID: xndxn1r3
    Snippet: BACKGROUND: There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer. METHODS: In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for t
    Document: BACKGROUND: There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer. METHODS: In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for their ability to generate E7-specific immune responses and antitumor effects in tumor-bearing mice. RESULTS: We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in the E7-specific CD8+ T cell immune responses and a decrease in the number of myeloid-derived suppressor cells in the tumor microenvironment of tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. Macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod. CONCLUSIONS: Thus, our data suggests that the combination of therapeutic HPV DNA vaccination with topical treatment with the TLR7 agonist imiquimod enhances the antitumor immunity induced by DNA vaccination. The current study has significant implications for future clinical translation.

    Search related documents:
    Co phrase search for related documents
    • active investigation and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7
    • active investigation and adaptive innate: 1
    • active investigation and local inflammation: 1
    • acute respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and adaptive innate effector: 1
    • acute respiratory syndrome coronavirus and local inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome coronavirus and local lymph: 1, 2
    • acute respiratory syndrome coronavirus and local microenvironment: 1
    • acute respiratory syndrome coronavirus and log rank test analyze: 1
    • acute respiratory syndrome coronavirus and long peptide: 1, 2, 3, 4, 5
    • acute respiratory syndrome coronavirus and lymphocyte population: 1, 2, 3
    • adaptive immune system and local inflammation: 1, 2
    • adaptive immune system and local microenvironment: 1
    • adaptive immune system and lymphocyte population: 1
    • adaptive innate and local infiltration: 1, 2
    • adaptive innate and local inflammation: 1, 2, 3, 4, 5
    • adaptive innate and local lymph: 1, 2
    • adaptive innate and local microenvironment: 1, 2